June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of Initial Visual Acuity on Cost of Diabetic Macular Edema Treatment
Author Affiliations & Notes
  • Deepthi M Reddy
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
    Retina Consultants of Alabama, Birmingham, AL
  • Richard M Feist
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
    Retina Consultants of Alabama, Birmingham, AL
  • Richard M. Feist
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
  • John O Mason
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
    Retina Consultants of Alabama, Birmingham, AL
  • michael A. Albert
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
    Retina Consultants of Alabama, Birmingham, AL
  • Martin L Thomley
    Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
    Retina Consultants of Alabama, Birmingham, AL
  • Claudia Ayala
    Retina Consultants of Alabama, Birmingham, AL
  • Footnotes
    Commercial Relationships Deepthi Reddy, None; Richard Feist, None; Richard Feist, None; John Mason, None; michael Albert, None; Martin Thomley, None; Claudia Ayala, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2144. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deepthi M Reddy, Richard M Feist, Richard M. Feist, John O Mason, michael A. Albert, Martin L Thomley, Claudia Ayala; Effect of Initial Visual Acuity on Cost of Diabetic Macular Edema Treatment. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2144. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effect of visual acuity on the overall cost of diabetic macular edema treatment before and during the era of anti-vascular endothelial growth factor (anti-VEGF) therapy.

Methods: A retrospective study was performed of two groups with clinically significant diabetic macular edema, who began treatment 10 years and 3 years ago, before and after the introduction of anti-VEGF therapy. Patients were stratified into subgroups with entry visual acuity better than 20/40 or 20/40 or worse. Treatment cost for each group and subgroup was calculated using current fee schedules for Medicare and the predominant private insurance carrier for the state of treatment (Alabama).

Results: The 10 year group received solely laser photocoagulation treatment while the 3 year group received both anti-VEGF and laser photocoagulation. Overall, the 3 year group had better visual retention during 2 years of follow up (mean logMAR of visual loss 0.03 versus 0.22, p=0.0029) at 2 years follow up) and a higher mean treatment cost. In the subgroup with 20/40 or worse vision, overall treatment costs ranged from 40% to 45% higher in the 3 year group and only 3% higher in the 10 year group.

Conclusions: Anti-VEGF treatment offers better visual prognosis in clinically significant diabetic macular edema but with a higher cost of treatment. Worse initial visual acuity may incur a higher cost of treatment.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×